Trending News Today: ICER Recommends Lower Price for MS Drug Siponimod
Top news of the day from across the health care landscape.
The Institute for Clinical and Economic Review (ICER) recommended that Novartis lower the price of its multiple sclerosis (MS) drug siponimod (Mayzent),
A new study suggests that patients with pediatric-onset multiple sclerosis (MS) face greater cognitive decline than patients who experience onset as adults,
On Friday, the Department of Health and Human Services sent to the White House for review a proposal to lower certain drugs in Medicare by linking them to lower prices paid in other countries,
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025